May 14, 2026
Three persistent myths continue to shape how pharmaceutical companies, biotechs, and even some regulators approach pharmacovigilance (PV), and each one carries a multi-million-dollar price tag.
Three persistent myths continue to shape how pharmaceutical companies, biotechs, and even some regulators approach pharmacovigilance (PV), and each one carries a multi-million-dollar price tag.
Safety recommendations for two medicinal products: the CAR-T cell therapy axicabtagene ciloleucel (Yescarta) and the tyrosine kinase inhibitor ponatinib (Iclusig).
World Hand Hygiene Day, observed annually on 5 May, has for 18 years championed the single most effective measure to prevent healthcare-associated infections (HAIs): timely and proper hand hygiene.
Regulatory safety information on medicinal products from national pharmacovigilance centres worldwide and the WHO Advisory Committee on Safety of Medicinal Products (ACSoMP).
Based on the WHO Guidelines for Malaria (August 2025) and Supporting Global Evidence
Medical overview of the history, types, and adverse effects of RPT, with a special focus on real-world pharmacovigilance data.
Comprehensive analysis of the MedDRA Version 29.0 IME list, including newly added terms, demoted terms, primary SOC changes, and the clinical significance of key updates. A comparative analysis with Version 28.1 highlights the evolution of this essential regulatory tool.
Advancing Medication Safety Through Knowledge and Vigilance
